By Steve Jenkinson, VP Drug Discovery and Safety Assessment, Metrion Biosciences
I’m delighted that the Safety Pharmacology Society have recognised the IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ as the ‘Most Impactful Safety Pharmacology Publication of the Year’ (published in Nature Reviews in Drug Discovery).
I co-chaired this Working Group prior to joining Metrion. As a team, we conducted an extensive survey to highlight similarities and differences in screening strategies and target panels across the pharmaceutical industry and as a result identified a number of opportunities for further optimisation within the secondary pharmacology assessment of novel compounds.
I extend congratulations to IQ Consortium and all other authors.
Read my earlier post about this work.
Brennan, R.J., Jenkinson, S., Brown, A. et al. The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nat Rev Drug Discov 23, 525–545 (2024). https://doi.org/10.1038/s41573-024-00942-3
By Steve Jenkinson, VP Drug Discovery and Safety Assessment, Metrion Biosciences
I’m delighted that the Safety Pharmacology Society have recognised the IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ as the ‘Most Impactful Safety Pharmacology Publication of the Year’ (published in Nature Reviews in Drug Discovery).
I co-chaired this Working Group prior to joining Metrion. As a team, we conducted an extensive survey to highlight similarities and differences in screening strategies and target panels across the pharmaceutical industry and as a result identified a number of opportunities for further optimisation within the secondary pharmacology assessment of novel compounds.
I extend congratulations to IQ Consortium and all other authors.
Read my earlier post about this work.
Brennan, R.J., Jenkinson, S., Brown, A. et al. The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nat Rev Drug Discov 23, 525–545 (2024). https://doi.org/10.1038/s41573-024-00942-3
By Steve Jenkinson, VP Drug Discovery and Safety Assessment, Metrion Biosciences
I’m delighted that the Safety Pharmacology Society have recognised the IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ as the ‘Most Impactful Safety Pharmacology Publication of the Year’ (published in Nature Reviews in Drug Discovery).
I co-chaired this Working Group prior to joining Metrion. As a team, we conducted an extensive survey to highlight similarities and differences in screening strategies and target panels across the pharmaceutical industry and as a result identified a number of opportunities for further optimisation within the secondary pharmacology assessment of novel compounds.
I extend congratulations to IQ Consortium and all other authors.
Read my earlier post about this work.
Brennan, R.J., Jenkinson, S., Brown, A. et al. The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nat Rev Drug Discov 23, 525–545 (2024). https://doi.org/10.1038/s41573-024-00942-3